Hei @Tallitonttu
Thank you for your questions. Below is the answer to your comment:
Medical has fallen short of its targets, and we have not succeeded in rectifying the situation last year. Corrective measures have been taken and are ongoing. We are not overly concerned about the decrease in Defence orders – one quarter does not change the overall picture yet (e.g., 4Q/24 order book jumped).
In Defence, the company aims to be, and already is, a reasonably significant player in the tactical communication disruption of defense forces. If the defense industry is viewed as a whole, there is no point in comparing us to defense giants. We focus on a targeted segment and intend to be winners there.
Let’s start with the company’s development trajectory – after the collapse of the product development services business (2017), the company has been able to grow its product revenue in line with its strategy while making strong investments in product development until 2021. Due to these investments, the result was effectively negative throughout this period. Cash flow-based earnings continuously improved due to increasing product sales. Accounting profit was generally slightly positive with the help of activations. At that time, the board was particularly concerned about the company’s future financial development, as a result of which the board decided to explore a potential new CEO as an alternative solution - the current CEO (Petri Toljamo) was also attempted to be recruited. After the then-CEO resigned, a new CEO was appointed in December 2022. Concurrently, the board announced long-term financial targets and a timeline (2024) for achieving these targets. The new CEO’s targets for 2023 (cost savings if necessary) and 2024 were clear minimum targets. The new CEO commendably carried out cost adjustments in the autumn of 2023, although the year’s revenue and profit were particularly disappointing. The profitability turnaround for 2024 was achieved barely, especially thanks to a volume order for SDR products from the Finnish Defence Forces. Development in the Medical and Engineering sectors was sluggish. Profit improvement achieved through restructuring is easier if product margins are good and more difficult if margins are poor. A change in CEO (if the CEO wished to continue) generally also indicates a lack of confidence from the board. With this change, the board aims for the operating management to have an even better broad understanding of the technologies we apply, so that the impacts of decisions on the future can be predicted more reliably. For the company to succeed in the future, the company’s operational clock speed must be increased, and things must be done with higher quality, faster, more focused, and more cost-effectively.
NATO membership has clearly improved Bittium’s opportunities in international tenders. The war in Ukraine and the Russian threat have generally raised the appreciation of the defense industry and created very strong demand in the sector, where the company has, for its part, seen a strong increase in said demand and an enlargement of tender sizes.
After three years, the war between Ukraine and Russia has become a war of attrition, where the demand for ammunition, missiles, armor, and transport equipment, among other things, has been prioritized in the procurement plans of various countries at this stage. Significant procurement needs are not resolved instantly, so it is certain that the amount of investment in defense will continue and grow. Bittium’s offering in tactical communication specifically supports the need for a reliable, secure, and easily adaptable and scalable command and control system. High data capacity enables comprehensive command and control and situational awareness, and our offering is excellently suited for operational command as well as particularly for air defense needs due to low latency. These are precisely what are needed. Despite the current static characteristics of the war of attrition emphasizing warfare, Bittium’s tactical communication system is the core of the command and control system in winning warfare. An easily adaptable, comprehensive, and scalable secure mobile command and control system, internationally compatible and suitable for the needs of various operations, will eventually replace passive fixed command and control systems – just as happened with the wired network. Bittium’s opportunities are very good due to its strong expertise and advanced technology.
In Medical, we are truly good at biosignal measurement. Faros has achieved an industry reference position in excellent signal quality measurement. Otherwise, we have not been able to integrate our biosignal expertise into creating competitive overall solutions. This integration includes software and approval procedures, where we have had significant shortcomings. At the same time, it must be stated that, in certain respects, FDA approvals have been very difficult for others as well. However, the situation is not lost, and we are doing everything we can to be able to share positive news in the future. Direction-changing measures have been initiated, and parts of them have already been announced. Focusing on what we do is the keyword.
Regarding Defence tenders, BAE cooperation, Finnish Defence Forces (PV) partnership, Nokia cooperation, and inorganic growth, we have disclosed what we can. When the topic arises, we will immediately provide more information.
Much has been said publicly about Nordic cooperation in the defense sector, and we cannot provide further information on that at this time. For the company, the Nordic dimension is an extremely important focus area.
We note your comment that the growth strategy is unambitious. We have stated the company-level numerical minimum targets (revenue (LV) growth and operating profit (OP) over 10%). We are thus seeking profitable annual absolute growth (compound interest). In the current situation, we consider our long-term financial targets realistic and provide an annual specified growth target and earnings range.
In 2024, Defence grew by 42.3%, Medical contracted by 12.6%, and Engineering by 15.6%. The entire company’s revenue grew by 13.2%, and the profit was 10.1%. The company-level targets were barely met. According to our guidance, we will grow at the company level by 11.5 – 23.3% this year, and operating profit will be over 10%. Based on the Q1/25 earnings release, it could be approximated that Defence must grow clearly over ten percent for the guidance to be maintained. The company believes it will achieve the set targets because the guidance was not changed.